Selecta Biosciences Inc., a clinical stage biotechnology company that is developing an innovative class of targeted antigen-specific immune therapies with synthetic vaccine particles (SVPs), recently announced that SVP may be crucial to developing an innovative vaccine technology targeting mucosal tissues.
Traditional vaccines and approaches have not been effective in treating many of the serious and chronic infectious diseases that survive in mucosa. The announcement, which was published in Science1, describes how recent discoveries with SVPs make it possible to create new vaccines for these diseases.
"There are several examples where conventional vaccines exacerbated infections in human clinical trials, including Chlamydia and RSV," Dr. Ulrich von Andrian, Mallinckrodt Professor of Immunopathology at Harvard Medical School and the co-founder of Selecta, said. "For the case of Chlamydia, we now have a mechanistic explanation for the failure of traditional vaccines combined with an SVP-based vaccination strategy that can overcome these challenges and create a vaccine with the potential to engender the desired robust immunoprotection."
The new studies were
conducted by Selecta’s founders, Robert Langer from the Massachusetts
Institute of Technology and Professors Ulrich von Andrian as well as
Omid Farokhzad at Harvard Medical School.
"The demonstration of protective immunity in a humanized model for Chlamydia infections is a real breakthrough," Selecta Biosciences President and CEO Dr. Werner Cautreels said. "Consistent with our company's strategy for infectious disease indications, we will actively seek value-adding partners with whom to develop and commercialize SVP for mucosal vaccines."